Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LBRXthis companyLB Pharmaceuticals Inc Common Stock	$42.38	-22.26×	1.87×	0×	-12.72×	-75.2%	0.0%	0.0%	0.0%	-8.4%	-9.9%	-6.3%	0.01×	9.91×	0×	41.44×	0.0%	2	25.27	2	C+
ACADAcadia Pharmaceuticals Inc.	$21.60	11.51×	3.69×	4.22×	29.19×	-252.2%	91.7%	9.8%	36.5%	31.9%	8.1%	2.3%	0.04×	-0.83×	0×	3.83×	0.0%	4	4.87	4	A-
ANROAlto Neuroscience, Inc.	$27.89	-8.13×	3.4×	0×	-5.68×	-73.1%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-10.1%	0.03×	2.86×	-26.88×	15.69×	0.0%	2	13.38	2	C+
DFTXDefinium Therapeutics, Inc.	$34.59	-6.5×	3.6×	0×	-5.26×	-91.2%	0.0%	0.0%	0.0%	-55.3%	-44.5%	-11.0%	0×	1.45×	-30.34×	6.29×	0.0%	3	12.28	2	C
DNLIDenali Therapeutics Inc.	$20.23	-5.56×	2.86×	0×	-5.48×	-94.9%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-14.6%	0.04×	0.34×	0×	9.16×	0.0%	3	2.05	2	C
MPLTMapLight Therapeutics, Inc.	$7.43	-4.8×	1.69×	0×	-4.56×	-86.3%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-17.9%	0.01×	0.25×	0×	20.01×	0.0%	2	5.7	2	C
Peer median	—	-5.56×	3.4×	0×	-5.26×	-91.2%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-11.0%	0.03×	0.34×	0×	9.16×	0.0%	3	5.7	2	—